Early growth response-1 mediates downregulation of telomerase in cervical cancer

Cancer Science

Volumn 99, Issue 7, 2008, Pages 1401-1406

  Akutagawa, Osamu ^a   Nishi, Hirotaka ^a   Kyo, Satoru ^b   Terauchi, Fumitoshi ^a   Yamazawa, Koji ^a   Higuma, Chinatsu ^a   Inoue, Masaki ^b   Isaka, Keiichi ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; LUCIFERASE; MESSENGER RNA; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR;

ANGIOGENESIS; ARTICLE; BINDING SITE; CANCER TISSUE; CARCINOGENESIS; CELL GROWTH; CONSENSUS SEQUENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME REGULATION; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE ACTIVATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INHIBITION KINETICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; UTERINE CERVIX CANCER; WESTERN BLOTTING;

BINDING SITES; CELL LINE, TUMOR; DOWN-REGULATION; EARLY GROWTH RESPONSE PROTEIN 1; FEMALE; HUMANS; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; TELOMERASE; UTERINE CERVICAL NEOPLASMS; WT1 PROTEINS;

EID: 44449151702     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00835.x     Document Type: Article

References (37)

1. Hamada H, Kobune M, Nakamura K et al. Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci 2005; 96: 149-56.
2. Painter RG, Lanson NA Jr, Jin Z et al. Conditional expression of a suicide gene by the telomere reverse transcriptase promoter for potential post-therapeutic deletion of tumorigenesis. Cancer Sci 2005; 96: 607-13.
3. Gashler A, Suklatme VP. Early growth response protein (Egr-1): Prototype of a zinc finger family of transcription factors. Prog Nucl Acid Res Mol Biol 1995; 50: 191-224.
4. Hung RP, Fan Y, Peng A et al. Suppression of human fibrosarcoma cell growth by transcription factor, Egr-1, involves downregulation of Bcl-2. Int J Cancer 1998; 77: 880-6.
5. Huang RP, Fan Y, De Bella I et al. Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int J Cancer 1997; 72: 102-9.
6. Kramer B, Meichle A, Hensel G et al. Characterization of a Krox-24/ Egr-1-responsive element in the human tumor necrosis factor promoter. Biochim Biophys Acta 1994; 1219: 413-21.
7. Rodeck U, Bossler A, Kari C et al. Expression of the wt1 Wilms' tumor gene by normal and malignant human melanocytes. Int J Cancer 1994; 59: 78-82.
8. Nishi H, Nishi KH, Johnson AC. Early growth response-1 gene mediates upregulation of epidermal growth factor receptor expression during hypoxia. Cancer Res 2002; 62: 827-34.
9. Madden SL, Cook DM, Morris JF et al. Transcriptional repression mediated by the WT1 Wilms tumor gene product. Science 1991; 253: 1550-3.
10. Hamilton TB, Barilla KC, Romaniuk PJ. High affinity binding sites for the Wilms'tumour suppressor protein WT1. Nucleic Acid Res 1995; 25: 277-84.
11. Decker EL, Nehmann N, Kampen N et al. Early growth response proteins (EGR) and nuclear factors of activated T cells (NFAT) form heterodimers and regulate proinflammatory cytokine gene expression. Nucleic Acid Res 2003; 31: 911-21.
12. Yan SF, Lu J, Zou YS et al. Hypozia associated induction of Egr-1 gene expression. J Biol Chem 1999; 274: 15 030-40.
13. Kato N, Kobayashi T, Honda H. Screening of stress enhancer based on analysis of gene expression profiles: Enhancement of hyperthermia-induced tumor necrosis by an MMP-3 inhibitor. Cancer Sci 2003; 94: 644-9.
14. Eid MA, Kumar MV, Iczkowski KA et al. Expression of early growth response genes in human postate cancer. Cancer Res 1998; 58: 2461-8.
15. Trenasari K, Takakura T, Ham MF et al. Telomere dysfunction and inactivation of the p16 (INK4a)/Rb pathway in pyothorax-associated lymphoma. Cancer Sci 2007; 98: 978-84.
16. Wright WE, Shay JW. Time, telomeres and tumors: Is cellular senescence more than an anticancer mechanism? Trends Cell Biol 1995; 5: 293-7.
17. Wu KJ, Grandori C, Amacker M et al. Direct activation of hTERT transcription by c-MYC. Nat Genet 1999; 21: 220-4.
18. Holt SE, Shay JW, Wright WE. Refining the telomere-telomerase hypothesis of aging and cancer. Nat Biotechnol 1996; 14: 836-9.
19. Haga K, Ohno S, Yugawa T et al. Efficient immortalization of primary human cells by p16INK4a-specific short hairpin RNA or Bmi-1, combined with introduction of hTERT. Cancer Sci 2007; 98: 147-54.
20. Nishi H, Ohyashiki K, Fujito A et al. Expression of telomerase subunits and localization of telomerase activation in hydatidiform mole. Placenta 1999; 20: 317-23.
21. Takakura M, Kyo S, Sowa Y et al. Telomerase activation by histone deacetylase inhibitor in normal cells. Nucl Acids Res 2001; 29: 3006-11.
22. Miura N, Nakamura H, Sato R et al. Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. Cancer Sci 2006; 97: 1366-73.
23. Kyo S, Takakura M, Taira T et al. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acid Res 2000; 28: 669-77.
24. Nishi H, Nakada T, Kyo S et al. Hypoxia-inducible factor mediate upregulation of telomerase. Mol Cell Biol 2004; 24: 6076-83.
25. Park YP, Choi SC, Kim JH et al. Up-regulation of Mac-2 binding protein by hTERT in gastric cancer. Int J Cancer 2007; 120: 813-20.
26. Kraeme K, Schmidt U, Fuessel S et al. Microarray analyses in bladder cancer cells: Inhibition of hTERT expression down-regulates EGFR. Int J Cancer 2006; 119: 1276-84.
27. Palmqvist R, Zhang A, Xu D et al. hTERT gene copy number is not associated with hTERT RNA expression or telomerase activity in colorectal cancer. Int J Cancer 2005; 116: 395-400.
28. Nishi H, Yahata N, Ohyashiki K et al. Comparison of telomerase activity in normal chorionic villi to trophoblastic diseases. Int J Oncol 1998; 12: 81-5.
29. Takakura M, Kyo S, Kanaya T et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 1999; 59: 551-7.
30. Calogero A, Cuomo L, D'Onofrio M et al. Expression of Egr-1 correlates with the transformed phenotype and the type of viral latency in EBV genome positive lymphoid cell lines. Oncogene 1996; 13: 2105-12.
31. Levin WJ, Press MF, Gaynor RB et al. Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study Group. Oncogene 1995; 11: 1261-9.
32. Yao J, Mackman N, Edgington T et al. Lipopolysaccharide induction of TNF promoter in human monocytes: Regulation by Egr-1, c-jun, and NF-κB transcription factors. J Biol Chem 1997; 272: 17 795-801.
33. de Belle I, Huang RP, Fan Y et al. p53 and Egr-1 additively suppress transformed growth in HT1080 cells, but Egr-1 counteracts p53-dependent apoptosis. Oncogene 1999; 18: 3633-42.
34. Scharnhorst V, Menke AL, Attema J et al. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity. Oncogene 2000; 19: 791-800.
35. Yatabe N, Kyo S, Maida Y et al. HIF-1-mediated activation of telomerase in cervical cancer cells. Oncogene 2004; 23: 3708-15.
36. Hockel M, Schlenger K, Hockel S et al. Hypoxia cervical cancers with low apoptotic index are highly aggressive. Cancer Res 1999; 59: 4525-8.
37. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply and metabolic microenvironment of human tumor. Cancer Res 1989; 49: 6449-65.